Role of Endoscopy in Primary Prophylaxis for Esophageal Variceal Bleeding

Clinics in Liver Disease

Volumn 14, Issue 2, 2010, Pages 231-250

  Albillos, Agustín ^a,b   Peñas, Beatriz ^a   Zamora, Javier ^a,c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

blockers; Cirrhosis; Endoscopic variceal ligation; Portal hypertension

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; ISOSORBIDE 5 NITRATE; METOPROLOL; NADOLOL; PLACEBO; PRAZOSIN; PROPRANOLOL; SIMVASTATIN; SPIRONOLACTONE; TIMOLOL;

ADJUVANT THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENDOSCOPIC VARICEAL LIGATION; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGOSCOPY; ESOPHAGUS PERFORATION; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FATIGUE; HEMODYNAMICS; HUMAN; LIGATION; LIVER CIRRHOSIS; MASS SCREENING; PORTAL HYPERTENSION; PRESSURE GRADIENT; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ESOPHAGEAL AND GASTRIC VARICES; ESOPHAGOSCOPY; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MASS SCREENING; PORTAL SYSTEM; TREATMENT OUTCOME;

EID: 77953031026     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.03.001     Document Type: Review

References (89)

1. D'Amico G., Garcia-Tsao G., and Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44 (2006) 217-231
2. de Franchis R. Updating consensus in portal hypertension: report of the Baveno II Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 33 (2000) 846-852
3. Groszmann R.J., García-Tsao G., Bosch J., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353 (2005) 2254-2261
4. Zoli M., Merkel C., Magalotti D., et al. Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am J Gastroenterol 95 (2000) 503-508
5. Merli M., Nicolini G., Angeloni S., et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 38 (2003) 266-272
6. Merkel C., Marin R., Angeli P., et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 127 (2004) 476-484
7. D'Amico G. Esophageal varices: from acceptance to rupture; natural history and prognostic indicators. In: Groszmann R.J., and Bosch J. (Eds). Portal hypertension in the 21st century (2004), Kluwer Academic Publishers, London 147-154
8. Carbonell N., Pauwels A., Serfaty L., et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 40 (2004) 652-659
9. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 31 (1988) 983-989
10. Merkel C., Zoli M., Siringo S., et al. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am J Gastroenterol 95 (2000) 2915-2920
11. Beppu K., Inokuchi K., Koyanagi N., et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 27 (1981) 213-218
12. Idezuki Y. General rules for recording endoscopic findings of esophagogastric varices. Japanese Society for Portal Hypertension. World J Surg 19 (1995) 420-422
13. Dagradi A.E., Stempien S.J., and Owens L.K. Bleeding esophagogastric varices. Arch Surg 92 (1966) 944-947
14. Westaby D., Melia W.M., MacDougal B.R., et al. Injection sclerotherapy for esophageal varices. A prospective randomized trial of different treatment schedules. Gut 25 (1984) 129-132
15. Winkfield B., Aubé C., Burtin P., et al. Inter-observer and intra-observer variability in hepatology. Eur J Gastroenterol Hepatol 15 (2003) 959-966
16. Calès P., Oberti F., Bernard-Chabert B., et al. Evaluation of Baveno recommendations for grading esophageal varices. J Hepatol 39 (2003) 657-659
17. de Franchis R., Pascal J.P., Ancona E., et al. Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol 15 (1992) 256-261
18. Madhotra R., Mulcahy H.E., Willner I., et al. Prediction of esophageal varices in patients with cirrhosis. J Clin Gastroenterol 34 (2002) 81-85
19. Christensen E., Fauerholdt L., Schlichting P., et al. Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone. Gastroenterology 81 (1981) 944-952
20. D'Amico G, Garcia-Tsao G, Cales P, et al. Diagnosis of portal hypertension: how and when. In: de Franchis R. Portal hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford (UK): Blackwell Science; 2001. p. 36-64.
21. García-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal haemorrhage in cirrhosis. AASLD Practice Guidelines. Hepatology 46 (2007) 922-938
22. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 43 (2005) 167-176
23. Saab S., DeRosa V., Nieto J., et al. Cost and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. Am J Gastroenterol 98 (2003) 763-770
24. Spiegel B.M., Targownik L., Dulai G.S., et al. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective?. Hepatology 37 (2003) 366-377
25. Arguedas M.R., Heudebert G.R., Eloubeidi M.A., et al. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal variceal bleeding. Am J Gastroenterol 97 (2002) 2441-2452
26. D'Amico G., Pagliaro L., and Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19 (1999) 475-505
27. Poynard T., Cales P., Pasta L., et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients form four randomized trials. Franco-italian Multicenter study group. N Engl J Med 324 (1991) 1532-1538
28. Chen W., Nikolova D., Frederiksen S.L., et al. Beta-blockers reduce mortality in cirrhotic patients with esophageal varices who have never bled (Cochrane review). J Hepatol 40 Suppl 1 (2004) 67
29. Grozsmann R.J., García-Tsao G., Bosch J., et al. Hemodynamic events in a prospective randomized trial of propanolol versus placebo in the prevention of the first variceal hemorrhage. Gastroenterology 99 (1990) 1401-1407
30. Merckel C., Bolognesi M., Sacerdoti D., et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 32 (2000) 930-934
31. Escorsell A., Bordas J.M., Castaneda B., et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 31 (2000) 1061-1067
32. Bureau C., Perón J.M., Alric L., et al. "A la carte" treatment of portal hypertension of portal hypertension: adapting therapy to hemodynamic response for the prevention of bleeding. Hepatology 36 (2002) 1361-1366
33. Turnes J., García-Pagan J.C., Abraldes J.G., et al. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 101 (2006) 506-512
34. Albillos A., Bañares R., Gonzalez M., et al. Value of hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 102 (2007) 1116-1126
35. D'Amico G., Garcia-Pagan J.C., Luca A., et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis a systematic review. Gastroenterology 131 (2006) 1611-1624
36. Feu F., Garcia-Pagan J.C., Bosch J., et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 346 (1995) 1056-1059
37. Villanueva C., Aracil C., Colomo A., et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 137 (2009) 119-128
38. La Mura V., Abraldes J.G., Raffa S., et al. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol 51 (2009) 279-287
39. Bosch J., Mastai R., Kravetz D., et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 4 (1984) 1200-1205
40. Cales P., Braillon A., Jiron M.I., et al. Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. Lack of correlation with oesophageal varices and gastrointestinal bleeding. Effect of propranolol. J Hepatol 1 (1985) 37-46
41. Feu F., Bordas J.M., Luca A., et al. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology 18 (1993) 1082-1089
42. Abraczinkas D.R., Ookubo R., Grace N.D., et al. Propranolol for the prevention of first variceal hemorrhage: a lifetime commitment?. Hepatology 34 (2001) 1096-1102
43. Bolognesi M, Balducci G, Garcia-Tsao G, et al. Complications in the medical treatment of portal hypertension. Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford (UK): Blackwell Science, 2001. p.180-203.
44. Khuroo M.S., Khuroo N.S., Farahat K.L., et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Aliment Pharmacol Ther 21 (2005) 347-361
45. García-Pagán J.C., Feu F., Bosch J., et al. Propanolol compared with propanolol plus isosorbide 5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 114 (1991) 869-873
46. Albillos A., Garcia-Pagan J.C., Iborra J., et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5- mononitrate in the treatment of portal hypertension. Gastroenterology 115 (1998) 116-123
47. Pietrosi G., D'amico G., Pasta L., et al. Isosorbide mononitrate (ISMN) with nadolol compared to nadolol alone for prevention of first variceal bleeding in cirrhosis. A double blind placebo-controlled randomized trial. J Hepatol 30 S1 (1999) 66
48. Merkel C., Marin R., Sacerdoti D., et al. Long-term results of clinical trial of nadolol with or without isosorbide 5-mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 31 (2000) 324-329
49. García Pagán J.C., Morillas R., Bañares R., et al. Propanolol plus placebo versus propanolol plus isosorbide 5 mononitrate in the prevention of first variceal bleed: a double blind RCT. Hepatology 37 (2003) 1260-1266
50. Albillos A. Pharmacological alternatives to β-blockers in primary prophylaxis. In: de Franchis R. Portal hypertension IV. Proceedings of the Fourth Baveno International Consensus Workshop on methodology of diagnosis and treatment. Oxford (UK): Blackwell; 2006. p. 177-180.
51. Abecasis R., Kravetz D., Fassio E., et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology 37 (2003) 359-365
52. Gonzalez-Abraldes J., Albillos A., Banares R., et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 121 (2001) 382-388
53. Schepke M., Werner E., Biecker E., et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 121 (2001) 389-395
54. Angelico M., Carli L., Piat C., et al. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 113 (1997) 1632-1639
55. Garcia-Pagan J.C., Villanueva C., Vila M.C., et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 121 (2001) 908-914
56. Borroni G., Salerno F., Cazzaniga M., et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol 37 (2002) 315-321
57. Bañares R., Moitinho E., Piqueras B., et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 30 (1999) 79-83
58. Tripathi D., Therapondos G., Lui H.F., et al. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 16 (2002) 373-380
59. Tripathi D., Ferguson J.W., Kochar N., et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 50 (2009) 825-833
60. Abraldes J.G., Albillos A., Bañares R., et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136 (2009) 1651-1658
61. Pagliaro L., D'Amico G., Sörensen T.I., et al. Prophylaxis of first bleeding. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 117 (1992) 59-70
62. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial. N Engl J Med 324 (1991) 1779-1784
63. Imperiale T.F., and Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 33 (2001) 802-807
64. Triantos C., Vlachogiannakos J., Armonis A., et al. Primary prophylaxis of variceal bleeding in cirrhotics unable to take β-blockers: a randomized trial of ligation. Aliment Pharmacol Ther 21 (2005) 1435-1443
65. Yoshida H., Mamada Y., Taniai N., et al. A randomized control trial of bi-monthly versus bi-weekly endoscopic variceal ligation of esophageal varices. Am J Gastroenterol 100 (2005) 2005-2009
66. De B.K., Ghoshal U.C., Das T., et al. Endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleed: preliminary report of a randomized controlled trial. J Gastroenterol Hepatol 14 (1999) 220-224
67. Sarin S.K., Lamba G.S., Kumar M., et al. Comparison of endoscopic ligation and propanolol for the primary prevention of variceal bleeding. N Engl J Med 340 (1999) 988-993
68. Lui H.F., Stanley A.J., Forrest E.H., et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propanolol and isosorbide mononitrate. Gastroenterology 123 (2002) 735-744
69. Lo G.H., Chen W., Chen M.H., et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 59 (2004) 333-338
70. Schepke M., Kleber G., Nurnberg D., et al. Ligation vs. propanolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 40 (2004) 65-72
71. Jutabha R., Jensen D.M., Martin P., et al. Randomized study comparing banding and propanolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 128 (2005) 870-881
72. Thuluvath P.J., Maheshwari A., Jagannath S., et al. A randomized controlled trial of beta-blockers versus endoscopic band ligation for primary prophylaxis: a large sample size is required to show difference in bleeding rates. Dig Dis Sci 50 (2005) 407-410
73. Psilopoulos D., Galanis P., Goulas S., et al. Endoscopic variceal ligation for prevention of first variceal bleeding: a randomized controlled trial. Eur J Gastroenterol Hepatol 17 (2005) 1111-1117
74. Lay C.S., Tsai Y.T., Lee F.Y., et al. Endoscopic variceal ligation versus propanolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 21 (2006) 413-419
75. Norberto L., Polese L., Cillo U., et al. A randomized study comparing ligation with propanolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl 13 (2007) 1272-1278
76. Chen C., Sheu M., and Su S. Prophylactic endoscopic variceal ligation (EVL) with multiple band ligator for esophageal varices. Gastroenterology 144 (1998) A1224
77. Song I., Shin J., Kim I., et al. A prospective randomized trial between the prophylactic endoscopic variceal ligation and propanolol administration for prevention of first bleeding in cirrhotic patients with high-risk esophageal varices. J Hepatol 32 Suppl 2 (2000) 41
78. De la Mora J., Farca-Belsaguy A., Uribe M., et al. Ligation vs. propanolol for primary prophylaxis of variceal bleeding using a multiple band ligator and objective measurements of treatment adequacy: preliminary results. Gastroenterology 118 (2000) 6512A
79. Gheorge C., Gheorge L., Vadan R., et al. Prophylactic banding ligation of high risk esophageal varices in patients on the waiting list for liver transplantation: an interim report. J Hepatol 36 Suppl 1 (2002) 38
80. Drastich P., Lata J., Petryl J., et al. Endoscopic variceal band ligation in comparison with propanolol in prophylaxis of first variceal bleeding in patients with liver cirrhosis. J Hepatol 42 Suppl 2 (2005) 79
81. Abdelfattah M.H., Rashed M.A., Elfakhry A.A., et al. Endoscopic variceal ligation versus pharmacological treatment for primary prophylaxis of variceal bleeding: a randomized study. J Hepatol 44 Suppl 2 (2006) 83A
82. García-Pagán J.C., and Bosch J. Endoscopic band ligation in the treatment of portal hypertension. Nature Clin Pract Gastroenterol Hepatol 2 (2005) 526-535
83. Albillos A. Preventing first variceal hemorrhage in cirrhosis. J Clin Gastroenterol 41 Suppl 3 (2007) S305-311
84. Bosch J., Berzigotti A., García-Pagán J.C., et al. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 48 Suppl (2008) S68-S92
85. Gluud L.L., Klingenberg S., Nikolova D., et al. Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systemic review of randomized trials. Am J Gastroenterol 102 (2007) 2841-2849
86. Imperiale T.F., Klein R.W., and Chalasani N. Cost-effectiveness analysis of variceal ligation vs. Beta-blockers for primary prevention of variceal bleeding in patients with cirrhosis. Hepatology 45 (2007) 870-878
87. Longacre A.V., Imaeda A., Garcia-Tsao G., et al. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage. Hepatology 47 (2008) 169-176
88. González R., Zamora J., Gomez-Camarero J., et al. Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 149 (2008) 109-122
89. Sarin S.K., Wadhawan M., Agarwal S.R., et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 100 (2005) 797-804